- Report
- September 2022
- 239 Pages
Global
From €6870EUR$7,500USD£5,839GBP
- Report
- February 2022
- 308 Pages
Global
From €8703EUR$9,500USD£7,396GBP
- Report
- January 2022
- 224 Pages
Global
From €6367EUR$6,950USD£5,411GBP
- Report
- October 2023
- 145 Pages
Global
From €2886EUR$3,150USD£2,452GBP
- Report
- February 2024
- 120 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- February 2024
- 112 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- July 2023
- 290 Pages
Global
From €3298EUR$3,600USD£2,803GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,093USD£3,079GBP
Ramucirumab is a monoclonal antibody used in the treatment of certain types of cancer. It is used in combination with other drugs to treat metastatic gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Ramucirumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Ramucirumab is a relatively new drug in the oncology market, but it has been gaining traction in recent years. It is used in combination with other drugs to treat a variety of cancers, and it has been shown to be effective in prolonging survival in some patients. It is also being studied in combination with other drugs for the treatment of other types of cancer.
Some of the companies in the Ramucirumab market include Eli Lilly, AstraZeneca, Merck, and Pfizer. Show Less Read more
